Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Half of induction responders achieved corticosteroid-free clinical remission without surgery at one year.

Rhea-AI Summary

Eli Lilly (NYSE: LLY) reported that Omvoh met the primary endpoint in its Phase 3 pediatric ulcerative colitis study. In SHINE-2, 81% achieved clinical response at Week 12. Among 52 responders ages 6 to 17, 50% achieved clinical remission at Week 52. The single-arm, open-label study used a benchmark derived from an adult placebo group, not a concurrent control group.

Among responders at Week 52, 71.2% achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission without surgery. Endoscopic improvement was 53.8%, and endoscopic remission was 44.2%. Through Week 52, four patients (6.3%) had serious adverse events, none considered treatment-related; two (3.2%) discontinued because of ulcerative colitis flare. No new safety signals were identified. Lilly plans global regulatory submissions to support a potential pediatric label expansion; Omvoh is currently approved for adults.

14 points · 1 major

PositiveiHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

0 major · 5 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major pointOmvoh met the primary endpoint: 50% of Week 12 responders achieved clinical remission at Week 52.
• Moderate point. Forward-looking: it has not happened yet and may not happen.Lilly plans global regulatory submissions supporting a potential pediatric ulcerative colitis label expansion.
• Minor pointWeek 12 clinical response reached 81% in the pediatric SHINE-2 study.
• Minor pointWeek 52 corticosteroid-free clinical remission without surgery reached 50% among Week 12 responders.
• Minor pointWeek 52 clinical response was 73.1% among Week 12 responders.

9 minor points

• Minor pointWeek 52 symptomatic remission reached 71.2% among Week 12 responders.
• Minor pointWeek 52 endoscopic improvement reached 53.8% among Week 12 responders.
• Minor pointWeek 52 endoscopic remission reached 44.2% among Week 12 responders.
• Minor pointSHINE-2 identified no new safety signals through Week 52; most treatment-emergent adverse events were mild to moderate.
• Minor pointNo deaths, malignancies, opportunistic infections or growth-related safety concerns were reported through Week 52.
• Minor pointPediatric development includes an ongoing long-term extension and Phase 3 pediatric Crohn's disease study.
• Minor pointLilly is studying Omvoh combinations with eltrekibart and zotemtegrast in ulcerative colitis.
• Minor pointLilly is studying Omvoh with an FXR agonist in Crohn's disease.
• Minor pointCOMMIT-UC and COMMIT-CD investigate concomitant mirikizumab and incretin-based therapy in adults with specified weight-related conditions.

Negative

• Minor pointSHINE-2 was single-arm and open-label, with its primary endpoint assessed against an adult placebo-derived benchmark.
• Minor pointWeek 52 efficacy covered only 52 Week 12 responders, rather than all 63 enrolled patients.
• Minor pointFour patients (6.3%) experienced serious adverse events through Week 52; none was considered treatment-related.
• Minor pointTwo patients (3.2%) discontinued treatment because of ulcerative colitis flare.
• Minor pointTreatment-emergent adverse events included upper respiratory tract infection, injection site reaction, ulcerative colitis, headache, nasopharyngitis and anemia.

Key Figures

Week 12 clinical response: 81% Week 52 clinical remission: 50% Corticosteroid-free clinical remission: 50% +5 more

Week 12 clinical response

81%

SHINE-2 induction

Week 52 clinical remission

50%

Primary endpoint among Week 12 responders (N=52)

Corticosteroid-free clinical remission

50%

Week 52, without surgery, among Week 12 responders

Symptomatic remission

71.2%

Week 52 among Week 12 responders

Endoscopic improvement

53.8%

Week 52 among Week 12 responders

Endoscopic remission

44.2%

Week 52 among Week 12 responders

Serious adverse events

6.3%

Through Week 52; none considered related to study treatment

Treatment discontinuations due to UC flare

3.2%

Through Week 52

Key Terms

il-23p19 inhibitor, single-arm, open-label, treatment-emergent adverse events, +1 more

5 terms

il-23p19 inhibitor medical

"Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results"

A medication that blocks the p19 part of interleukin‑23, a signaling protein that tells certain immune cells to cause inflammation; by stopping that signal these drugs calm inappropriate immune attacks seen in conditions like psoriasis and inflammatory bowel disease. For investors, successful IL‑23p19 inhibitors can mean clear clinical trial pathways, recurring prescriptions and sizable market demand—think of them as turning down a misfiring thermostat to prevent damage elsewhere in the house.

single-arm technical

"In the single-arm, open-label study"

A single-arm study is a clinical trial that gives all participants the same treatment and does not include a separate comparison group or placebo. Think of it like testing a new recipe by serving it to diners without offering a control dish — you can see how people respond, but you can’t directly compare results to another option. For investors, single-arm trials can speed development and reduce cost but leave more uncertainty about how a treatment stacks up against existing therapies and how regulators will view the evidence.

open-label technical

"In the single-arm, open-label study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

treatment-emergent adverse events medical

"The most common treatment-emergent adverse events in SHINE-2 were"

Events or symptoms that either appear for the first time or get worse after a patient starts a treatment; think of new or intensified side effects that show up once medicine or a medical device is used. Investors watch these closely because they affect whether a therapy can gain regulatory approval, be prescribed widely, or face legal and commercial setbacks—similar to how early customer complaints can sink a new product’s prospects.

serious adverse event medical

"four patients (6.3%) experienced a serious adverse event"

A serious adverse event is an unexpected medical problem tied to a treatment or trial that leads to death, is life‑threatening, requires (or prolongs) hospitalization, causes lasting disability, or results in a birth defect. Investors care because such events can prompt regulatory investigations, clinical holds, added safety studies, or product withdrawals—like a major car recall that halts sales, adds costs and damages trust, potentially affecting a company’s value and timelines.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Building on Omvoh's approved use and durable efficacy in adults, Lilly plans to submit these data to global regulators to support a potential label expansion for pediatric ulcerative colitis

More than 80% of patients responded to Omvoh induction, and half of responders, ages 6 to 17, were in clinical remission at one year in Phase 3 SHINE-2 study

In key secondary outcomes, 71.2% of patients who responded to Omvoh induction achieved symptomatic remission and 50% achieved corticosteroid-free clinical remission at one year without surgery

INDIANAPOLIS, Oct. 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive late-breaking one-year results from the Phase 3 SHINE-2 study of Omvoh (mirikizumab-mrkz) in pediatric patients ages 6 to 17 with moderately to severely active ulcerative colitis (UC), including clinical, symptomatic and endoscopic outcomes. In the single-arm, open-label study, 81% of patients achieved clinical response to Omvoh induction at Week 12. Among responders, 50% achieved clinical remission at Week 52, meeting the study's primary endpoint.* Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric UC. These results were presented as a late-breaking oral presentation at United European Gastroenterology (UEG) Week 2026.¹ 

Omvoh is currently approved for adults with moderately to severely active UC. The safety and effectiveness of Omvoh in pediatric patients are currently being evaluated in clinical studies. Lilly plans to submit these data to global regulators to support a potential label expansion. If approved, Omvoh would be the first IL-23p19 inhibitor indicated for pediatric UC.

"For children and adolescents, the persistent bowel urgency, abdominal pain and unpredictability of ulcerative colitis can make a normal childhood feel out of reach, especially when symptoms return after previous treatments," said Mark Genovese, M.D., senior vice president of Lilly Immunology development. "Already approved for adults with ulcerative colitis, Omvoh is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis. We look forward to working with regulators to potentially make Omvoh available to children and adolescents living with this disease, who continue to face substantial disease burden and ongoing unmet needs."

Unmet need in pediatric ulcerative colitis
UC affects more than 26,000 children and adolescents in the U.S.³ Although relatively uncommon, pediatric-onset UC is often more extensive and severe than disease that begins in adulthood.⁴ Up to half of children treated with corticosteroids become dependent on them, and up to one-third require surgery within a year.⁴

SHINE-2 evaluated Omvoh in a pediatric population with high disease burden and significant unmet need, including 54% of enrolled patients who had previously experienced biologic treatment failure. Half entered the study with severe disease activity as measured by the Pediatric Ulcerative Colitis Activity Index.¹

"For children with ulcerative colitis, every year spent relying on corticosteroids or facing the possibility of surgery can have important implications for growth, development and quality of life," said Marla C. Dubinsky, M.D., Professor of Pediatrics and Medicine at the Icahn School of Medicine at Mount Sinai, Chief of Pediatric Gastroenterology and Nutrition at Mount Sinai Kravis Children's Hospital. "Considering these challenges, the finding that half of the pediatric patients who responded to Omvoh achieved corticosteroid-free clinical remission without surgery at one year is particularly meaningful, especially in a population where many patients had previously experienced treatment failure with advanced therapies."

One-year results from SHINE-2 in children and adolescents with ulcerative colitis
Of the patients enrolled in SHINE-2, 81% achieved clinical response at Week 12. Among responders, ages 6 to 17, efficacy was sustained across multiple clinical, symptomatic and endoscopic outcomes at Week 52, including:

• 50% clinical remission (primary endpoint)*
• 50% corticosteroid-free clinical remission without surgery^†  
• 73.1% clinical response^‡ 
• 71.2% symptomatic remission^¶ 
• 53.8% endoscopic improvement^# 
• 44.2% endoscopic remission**

The pediatric Week 52 clinical remission rate was similar to that observed among adult Week 12 responders treated with Omvoh in LUCENT-2 (50.7%).¹ This descriptive observation was separate from the primary endpoint analysis and should not be interpreted as a direct comparison between studies.

These one-year findings build on the early clinical, symptomatic and endoscopic improvements observed at Week 12, which were presented as a late-breaking oral presentation at the American College of Gastroenterology 2026 Annual Scientific Meeting.⁵

Safety findings from SHINE-2
Through Week 52 in SHINE-2, the safety profile of Omvoh in children and adolescents was consistent with its established safety profile in adults, with no new safety signals identified. The most common treatment-emergent adverse events in SHINE-2 were upper respiratory tract infection, injection site reaction, UC, headache, nasopharyngitis and anemia. Most treatment-emergent adverse events were mild to moderate in severity. Through Week 52, four patients (6.3%) experienced a serious adverse event; none was considered related to study treatment. Two patients (3.2%) discontinued treatment because of UC flare. No deaths, malignancies, opportunistic infections or growth-related safety concerns were reported through Week 52.¹

Omvoh has received regulatory approvals for the treatment of moderately to severely active UC and moderately to severely active Crohn's disease in adults and has been approved in 47 countries around the world. In UC, Omvoh is also approved as a single-injection maintenance regimen in several countries around the world including the U.S., EU, Canada and Japan.

Lilly continues to study mirikizumab in pediatric inflammatory bowel disease, including a long-term extension study in UC and Crohn's disease (NCT04844606) and an ongoing Phase 3 study in pediatric Crohn's disease (NCT05509777). Lilly is also evaluating mirikizumab through combination approaches and novel mechanisms aimed at delivering breakthrough induction efficacy while maintaining long-term remission and safety. These include studies in UC with eltrekibart (NCT06598943), a monoclonal antibody that targets neutrophil-driven inflammation, and with zotemtegrast (NCT07186101), an oral α4β7 integrin inhibitor. In Crohn's disease, Lilly is studying mirikizumab in combination with an FXR agonist (NCT07483099). The COMMIT-UC (NCT06937086) and COMMIT-CD (NCT06937099) trials are investigating the concomitant use of mirikizumab and an incretin-based therapy in adults with UC or Crohn's disease and obesity or overweight with at least one additional weight-related comorbid condition.

Disclosure: Dr. Dubinsky is a paid consultant for Lilly. She has not been compensated for any media work.

About SHINE-2
SHINE-2 is a Phase 3, multicenter, single-arm, open-label study evaluating mirikizumab in pediatric patients with moderately to severely active UC. A total of 63 participants, ages 4 to 17, were enrolled and received weight-based intravenous induction every four weeks for three doses (300 mg for patients >40 kg; 5 mg/kg for patients ≤40 kg). At Week 12, 52 patients entered the maintenance period as clinical responders and received weight-based subcutaneous mirikizumab every four weeks through Week 52. The primary endpoint was evaluated against a pre-specified benchmark derived from the adult placebo remission rate in the Phase 3 LUCENT-2 study.* The Week 52 efficacy results are reported for the Week 12 responder population (N=52; ages 6 to 17); safety results are based on all enrolled patients (N=63).

Patients completing SHINE-2 may be eligible to continue in SHINE-ON, an ongoing long-term extension study evaluating mirikizumab in pediatric patients with UC or Crohn's disease.

About Omvoh
Omvoh (mirikizumab-mrkz) is an interleukin-23p19 (IL-23p19) antagonist indicated for the treatment of moderately to severely active ulcerative colitis and Crohn's disease in adults. Omvoh selectively targets the p19 subunit of IL-23 and inhibits the IL-23 pathway. Inflammation due to over-activation of the IL-23 pathway plays a critical role in the pathogenesis of inflammatory bowel disease.²  The safety and effectiveness of Omvoh have not been established in pediatric patients.

Omvoh and its delivery device base are trademarks owned by Eli Lilly and Company.

Endnotes and References

*Clinical remission was defined as stool frequency (SF) subscore=0 or 1, rectal bleeding (RB) subscore=0 and endoscopic subscore (ES)=0 or 1 (excluding friability). The primary endpoint was met by exceeding a pre-specified benchmark based on the placebo remission rate in adults from the Phase 3 LUCENT-2 study. The lower bound of the 80% credible interval for the Week 52 pediatric remission rate among Week 12 responders (42.8%) exceeded the upper bound of the 90% credible interval for the adult placebo remission rate in LUCENT-2 (32.6%). Week 52 efficacy was assessed among the 52 patients who entered the maintenance period as Week 12 clinical responders, based on response status recorded by study sites.  
†Corticosteroid-free clinical remission without surgery: clinical remission at Week 52 without surgery, and no corticosteroid use for at least 12 weeks prior to Week 52. 
‡Clinical response: a decrease in the MMS of ≥2 points and ≥30% decrease from induction baseline plus a decrease of ≥1 point in the RB subscore from induction baseline or an RB subscore of 0 or 1.   
¶Symptomatic remission: SF=0, or SF=1 with ≥1-point decrease from baseline and RB=0. 
#Endoscopic improvement: ES=0 or 1, excluding friability.
**Endoscopic remission: ES=0.

¹Turner D, et al. Mirikizumab, the first IL-23p19 inhibitor to demonstrate sustained efficacy through 1 year in pediatric moderately-to-severely active ulcerative colitis: efficacy and safety findings from SHINE-2. United European Gastroenterology Week 2026; October 19, 2026; Barcelona, Spain.
²Omvoh. Prescribing Information. Lilly USA, LLC. 
³Kappelman MD, Brensinger C, Parlett LE, Hurtado-Lorenzo A, Lewis JD. Prevalence of pediatric inflammatory bowel disease in the United States: pooled estimates from three administrative claims data sources. Gastroenterology. 2025;168(5):980-982.e2. doi:10.1053/j.gastro.2024.11.004
⁴Wine E, Aloi M, Van Biervliet S, et al. Management of paediatric ulcerative colitis, part 1: Ambulatory care— an updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation. J Pediatr Gastroenterol Nutr. 2025;81(3):765-815. doi:0.1002/jpn3.70097
⁵Dubinsky M, et al. Mirikizumab induction therapy achieves early clinical, endoscopic, and biomarker improvement in children and adolescents with moderately to severely active ulcerative colitis: Week 12 results from the SHINE-2 study. American College of Gastroenterology 2026 Annual Scientific Meeting; October 14, 2026; Nashville, TN. 

Indications and Usage for Omvoh^® (mirikizumab-mrkz) (in the United States)
Omvoh is an interleukin-23 antagonist indicated for adults with:

• Moderately to severely active ulcerative colitis
• Moderately to severely active Crohn's disease

Important Safety Information for Omvoh (mirikizumab-mrkz)

CONTRAINDICATIONS

Omvoh is contraindicated in patients with a history of serious hypersensitivity reaction to mirikizumab-mrkz or any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions
Serious hypersensitivity reactions, including anaphylaxis during intravenous infusion, have been reported with Omvoh administration. Infusion-related hypersensitivity reactions, including mucocutaneous erythema and pruritus, were reported during induction. If a severe hypersensitivity reaction occurs, discontinue Omvoh immediately and initiate appropriate treatment.

Infections
Omvoh may increase the risk of infection. Do not initiate treatment with Omvoh in patients with a clinically important active infection until the infection resolves or is adequately treated. In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing Omvoh. Instruct patients to seek medical advice if signs or symptoms of clinically important acute or chronic infection occur. If a serious infection develops or an infection is not responding to standard therapy, monitor the patient closely and do not administer Omvoh until the infection resolves.

Tuberculosis
Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Omvoh. Do not administer Omvoh to patients with active TB infection. Initiate treatment of latent TB prior to administering Omvoh. Consider anti-TB therapy prior to initiation of Omvoh in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after Omvoh treatment. In clinical trials, subjects were excluded if they had evidence of active TB, a history of active TB, or were diagnosed with latent TB at screening.

Hepatotoxicity
Drug-induced liver injury in conjunction with pruritus was reported in a clinical trial subject following a longer than recommended induction regimen. Omvoh was discontinued. Liver test abnormalities eventually returned to baseline. Evaluate liver enzymes and bilirubin at baseline and for at least 24 weeks of treatment. Monitor thereafter according to routine patient management. Consider other treatment options in patients with evidence of liver cirrhosis. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. Interrupt treatment if drug-induced liver injury is suspected, until this diagnosis is excluded. Instruct patients to seek immediate medical attention if they experience symptoms suggestive of hepatic dysfunction.

Immunizations
Avoid use of live vaccines in patients treated with Omvoh. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating therapy, complete all age-appropriate vaccinations according to current immunization guidelines. No data are available on the response to live or non-live vaccines in patients treated with Omvoh.

ADVERSE REACTIONS
Most common adverse reactions associated with Omvoh (≥2% of subjects and at a higher frequency than placebo) in ulcerative colitis treatment are upper respiratory tract infections and arthralgia during the induction study (UC-1), and upper respiratory tract infections, injection site reactions, arthralgia, rash, headache, and herpes viral infection during the maintenance study (UC-2). Most common adverse reactions associated with Omvoh in the Crohn's disease study (CD-1) (≥5% of subjects and at a higher frequency than placebo) are upper respiratory tract infections, injection site reactions, headache, arthralgia, and elevated liver tests.

Omvoh injection is available as a 300 mg/15 mL solution in a single-dose vial for intravenous infusion, and as a 100 mg/mL solution or a 200 mg/2 mL solution in a single dose prefilled pen or prefilled syringe for subcutaneous injection. Refer to the Prescribing Information for dosing information.

MR HCP ISI CD APP

Click to access provided Prescribing Information and Medication Guide. See Instructions for Use provided with the device.

About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. P-LLY

Trademarks and Trade Names
All trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Omvoh (mirikizumab-mrkz) as a treatment for people with moderately to severely active ulcerative colitis and moderately to severely active Crohn's disease and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development and commercialization. Among other things, there is no guarantee that future study results will be consistent with the results to date, or that Lilly will execute its strategies as planned. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

Refer to:	Kelly Hoffman; kelly.hoffman@lilly.com (Media)
	Michael Czapar; czapar_michael_c@lilly.com (Investors)

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lillys-omvoh-mirikizumab-mrkz-meets-primary-endpoint-of-clinical-remission-and-is-the-first-il-23p19-inhibitor-to-report-one-year-phase-3-results-in-pediatric-ulcerative-colitis-302911320.html

SOURCE Eli Lilly and Company

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Lilly's Omvoh pediatric ulcerative colitis trial show at one year?

In SHINE-2, 50% of Week 12 responders achieved clinical remission at Week 52, meeting the primary endpoint. The Week 52 efficacy population comprised 52 patients ages 6 to 17. Among these responders, 50% also achieved corticosteroid-free clinical remission without surgery.

Does Lilly plan to seek pediatric approval for Omvoh?

Lilly plans to submit the SHINE-2 data to global regulators to support a potential pediatric ulcerative colitis label expansion. Omvoh is currently approved for adults with moderately to severely active ulcerative colitis and Crohn's disease.

How was the primary endpoint benchmark set in Lilly's SHINE-2 Omvoh trial?

The primary endpoint used a pre-specified benchmark derived from the adult placebo remission rate in LUCENT-2. The lower bound of the 80% credible interval for pediatric Week 52 remission was 42.8%, exceeding the upper bound of the 90% credible interval for adult placebo remission, 32.6%.

What did corticosteroid-free remission mean in Lilly's pediatric Omvoh trial?

Corticosteroid-free clinical remission without surgery meant clinical remission at Week 52 without surgery and no corticosteroid use for at least 12 weeks before Week 52.